Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scandium-44
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Scandium-44 ($^{44}\text{Sc}$) is an investigational positron-emitting radiometal with a half-life of approximately 4 hours (3.97–4.04 h) and a high positron branching ratio of about 94%. It decays to non-toxic calcium-44. Due to its favorable physical properties, including a longer half-life than gallium-68 ($^{68}\text{Ga}$), scandium-44 is highly suitable for positron emission tomography (PET) imaging, allowing for longer imaging windows and centralized distribution. Its coordination chemistry is similar to radiolanthanides, enabling it to be conjugated to various targeting vectors (such as peptides, small molecules, and antibodies) using chelators like DOTA or NODAGA. Scandium-44 is also utilized as a diagnostic partner for therapeutic radionuclides like scandium-47 or lutetium-177 in theranostic applications.
- Other names
- 44ScSc-44Sc44Sc 44scandium-44 acetatescandium44 acetatescandium 44 acetatescandium-44 chloridescandium44 chloridescandium 44 chloride
Beyond the preview
Go deeper on scandium-44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scandium-44.